Key result
Therapeutic targeting of STAT3 for cardiovascular disease and arrhythmias requires maintaining balanced STAT3 function rather than inducing large-scale perturbations.
Why the study?
Cardiac fibrosis contributes to cardiovascular disease and arrhythmia, and STAT3 has emerged as a critical integrator of pro-fibrotic signals in cardiac fibroblasts downstream of established signaling networks.
This review highlights the multimodal role of STAT3 in cardiac fibroblast signaling and suggests that balanced modulation of STAT3 could be a therapeutic strategy for cardiac fibrosis and arrhythmias.
Answers are grounded in this paper and cite their sources.
Caution against unbalanced STAT3 perturbations in patients; leaves open precise modulation strategies for future trials.
Introduction: Cardiac fibrosis contributes to the development of cardiovascular disease (CVD) and arrhythmia. Cardiac fibroblasts (CFs) are collagen-producing cells that regulate extracellular matrix (ECM) homeostasis. A complex signaling network has been defined linking environmental stress to changes in CF function and fibrosis. Signal Transducer and Activator of Transcription 3 (STAT3) has emerged as a critical integrator of pro-fibrotic signals in CFs downstream of several established signaling networks.Areas covered: This article provides an overview of STAT3 function in CFs and its involvement in coordinating a vast web of intracellular pro-fibrotic signaling molecules and transcription factors. We highlight recent work elucidating a critical role for the fibroblast cytoskeleton in maintaining spatial and temporal control of STAT3-related signaling . Finally, we discuss potential opportunities and obstacles for therapeutic targeting of STAT3 to modulate cardiac fibrosis and arrhythmias. Relevant publications on the topic were identified through Pubmed.Expert opinion: Therapeutic targeting of STAT3 for CVD and arrhythmias presents unique challenges and opportunities. Thus, it is critical to consider the multimodal and dynamic nature of STAT3 signaling. Going forward, it will be beneficial to consider ways to maintain balanced STAT3 function, rather than large-scale perturbations in STAT3 function.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2020) conducted a review in Cardiac fibrosis and arrhythmias. Therapeutic targeting of STAT3 was evaluated. Therapeutic targeting of STAT3 for cardiovascular disease and arrhythmias requires maintaining balanced STAT3 function rather than inducing large-scale perturbations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: